This study investigated whether gemcitabine, adsorbed onto activated carbon particles (GEM-AC), increased the concentration of gemcitabine at the injection site and in the regional lymph nodes in an experimental animal model and a clinical study. The adsorption isotherm for GEM-AC was defined, and the concentration and distribution of gemcitabine in rats (n = 50) and in patients with pancreatic cancer (n = 8) was investigated. Drug concentrations in plasma, tumour samples, lymph nodes and at the injection site were measured after GEM-AC or gemcitabine solution (GEM-Sol) were subcutaneously injected into the left hind foot pad in rats, or into pancreatic tumours in patients. These experiments showed that GEM-AC was selectively delivered to the regional lymph nodes and the injection site, from which it slowly released greater amounts of gemcitabine to maintain the free concentration of gemcitabine at a relatively high level for a long period of time. The administration of GEM-AC might enhance the anticancer effects of gemcitabine.
Introduction
For over a decade, activated carbon particles with a diameter of 21 nm have been used as drug vehicles in lymphatic chemotherapy, intraperitoneal chemotherapy and intratumoral injection therapy. 1 -10 When injected into tissues, activated carbon particles are taken up selectively by lymph vessels and reach regional lymph nodes. 11, 12 In addition, activated carbon particles can adsorb large amounts of anticancer agents and release them slowly over protracted time-periods. 2, 7 In clinical situations, drugs including methotrexate, 1 -5 mitomycin 4 -9 and carboplatin 10 have been bound to activated carbon particles, to increase drug concentrations and prolong the duration of drug action. 1 -10 F Guo, X Mao, J Wang et al.
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Occult in onset, pancreatic carcinoma usually progresses rapidly. Approximately 70 -80% of patients with pancreatic carcinoma are not eligible for surgical resection at the time of diagnosis and the median survival is 7.5 months. 13 -16 Lymph node metastasis occurs in the early stages of pancreatic carcinoma; however, neither standard lymphadenectomy nor extended lymphadenectomy achieve satisfactory results. 17 -19 Thus, there is an urgent need to control lymph node metastases and tumour progression in patients with pancreatic carcinoma who are unsuitable for curative resections (due to locally advanced tumours, or surgical contraindications such as senility or severe cardiopulmonary disease). Since gemcitabine is the standard therapy for pancreatic cancer, 20 -22 a new formulationgemcitabine-adsorbed activated carbon particles (GEM-AC) -was developed for intratumoral injection, to increase the gemcitabine concentration and prolong its duration of action.
The present study aimed to define the adsorption isotherm of GEM-AC and evaluate the concentration and distribution characteristics of GEM-AC in healthy rats and in patients with pancreatic cancer.
Materials and methods

ADSORPTION EQUILIBRIUM TIME
Activated carbon particles (50 mg; Chongqing Lummy Pharmaceutical Co. Ltd, Chongqing, China) with a diameter of 21 nm and a surface area of 1480 m 2 /g, were mixed with 30 mg polyvinylpyrrolidone K-30 (Shanghai H&C Fine Chemical Co. Ltd, Shanghai, China) in 3 ml of saline. Ultrasonic shaking of the mixture was undertaken to form a suspension and 20 mg gemcitabine (Jiangsu Hansoh Pharmaceutical Co. Ltd, Jiangsu, China) was added. The mixture (pH 7.2) was adjusted to 10 ml with saline and then ultrasonically shaken at 37°C for 5, 10, 15, 20, 25, 30 and 35 min. At each time-point, after removing the activated carbon particles with filter paper, the concentration of gemcitabine in the filtrate was measured by high-performance liquid chromatography (HPLC) (Shimadzu LC-10AD chromatograph; Shimadzu Co., Kyoto, Japan) and an ultraviolet (UV) detector (Shimadzu SPD-10A UV detector; Shimadzu Co.) at a wavelength of 268 nm. This experiment was repeated three times.
ADSORPTION IN VITRO
A total of 20 mg gemcitabine was dissolved in 10 ml saline (pH 7.2). Activated carbon was added to the solution at 1, 2, 3, 4, 5 and 6 mg/ml, then the mixture was ultrasonically shaken at 37°C for 30 min. After the adsorption reached equilibrium, the activated carbon was removed with a filter and the concentration of gemcitabine was measured by HPLC. This experiment was repeated three times.
ADSORPTION ISOTHERM
At every time-point, the concentration of gemcitabine in the free state was assumed to be x and was expressed in µg/ml. The amount of gemcitabine adsorbed onto the activated carbon particles was assumed to be y and was expressed in µg/mg. The equilibrium points were set on a log-log scale of x and y and the adsorption isotherm line was drawn.
DRUG PREPARATION
Activated carbon particles (50 mg), 30 mg polyvinylpyrrolidone K-30 and 20 mg gemcitabine were mixed in saline and the volume was adjusted to 1 ml with the addition of saline drops. The mixture was ultrasonically shaken at 37°C for 30 min to reach the adsorption equilibrium. This F Guo, X Mao, J Wang et al.
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produced the new dosage formulation GEM-AC, which consisted of a suspension containing 50 mg/ml of activated carbon particles, 30 mg/ml of polyvinylpyrrolidone K-30 and 20 mg/ml of gemcitabine. Gemcitabine solution (GEM-Sol), which contained 20 mg/ml of gemcitabine in saline, was prepared as the control formulation.
DRUG DISTRIBUTION IN RATS
Fifty female Sprague-Dawley rats weighing 250 g, 9 weeks of age were obtained from Fudan University Animal Centre (Shanghai, China) and were divided into two groups: the GEM-AC group (n = 25) and the GEM-Sol group (n = 25). All animals were kept under conditions of constant temperature (mean ± SD 22 ± 2°C), under a standard 12-h light/12-h dark cycle with free access to food and water. They were cared for in compliance with Rats in the GEM-AC and GEM-Sol (control) groups received either 0.2 ml GEM-AC or 0.2 ml GEM-Sol injected subcutaneously into the left hind foot pad. Five rats were sacrificed at each of 0.5, 1, 2, 4 and 7 h after injection in each group. Then, 2 ml blood was taken by heart paracentesis and plasma was separated from whole blood by centrifugation at 450 g for 5 min at 4°C. Tissue from the injection site, the left popliteal lymph nodes (the firstlevel regional nodes) and the para-aortic lumbar lymph nodes (the second-level regional nodes) was removed and homogenized in distilled water. Tissue fractions and carbon particles were removed by centrifugation at 800 g for 5 min. Plasma and the supernatant fluid from the tissue samples were kept at −80°C prior to analysis. The concentration of gemcitabine in the biological samples was measured by HPLC and UV detection as described previously, 23 and expressed in µg/ml or µg/g.
DRUG DISTRIBUTION IN PATIENTS
Patients with a tumour of the body or tail of the pancreas who underwent distal pancreatectomy with splenectomy at Huashan Hospital (Shanghai Medical College, Fudan University, Shanghai, China), between January 2007 and August 2010, were recruited into the study. Patients in good physical condition, with no known metastases, in whom preoperative examinations showed that the tumour could be resected, were included.
On the basis of a central computergenerated randomization list, eligible patients were randomized to the two treatment groups: the GEM-AC group and the GEM-Sol (control) group, which received either 0.2 ml GEM-AC or 0.2 ml GEM-Sol, respectively, injected into the tumour after surgical exploration. After mobilization of the body and tail of the pancreas, the neck of the pancreas was transected along the superior mesenteric vein and the portal vein. A blood sample was taken immediately from the portal vein. At the same time, 0.4 -0.5 g tumour tissue was sampled opposite the injection point. The number 10 (hilus of the spleen) and the number 11 (trunk of the splenic artery) lymph nodes were isolated from operative specimens. Half of each lymph node was used for pathological examinations; the other half was used to detect drug concentrations. The gemcitabine concentrations in specimens were measured as described previously 23 for rat tissue samples.
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All patients received verbal and written information about the study before providing written consent. The study protocol was approved by the Ethics Committee of Huashan Hospital, Fudan University.
STATISTICAL ANALYSES
Statistical analyses were performed using SPSS ® statistical software, version 15.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The gemcitabine concentration was expressed as the detection value and mean value, in both animals and patients. The gemcitabine concentration in the number 10 and 11 lymph nodes in patients was expressed as mean ± SD. Differences between the two groups were analysed using the nonparametric Mann-Whitney U-test. Statistical significance was set at P < 0.05.
Results
ADSORPTION EQUILIBRIUM TIME
By measuring the concentrations of gemcitabine in the suspension, the amount of gemcitabine adsorbed onto the activated carbon could be calculated at different timepoints. The mean amount of gemcitabine that was adsorbed plotted against the duration for which the suspension was ultrasonically shaken is presented in Fig. 1 . The adsorption equilibrium time was < 30 min when the suspension was ultrasonically shaken at 37°C at a pH of 7.2 in saline.
ADSORPTION ISOTHERM
The adsorption isotherm was defined by y = 146.54x 0.18 (R 2 = 0.9924) at 37°C and pH 7.2 in saline, where x is the concentration of gemcitabine in the free state (µg/ml) and y is the amount of gemcitabine adsorbed onto activated carbon particles (µg/ml). The adsorption isotherm is shown in Fig. 2 . At equilibrium in the GEM-AC formulation the gemcitabine concentration in the free state was 250 µg/ml and 19 750 µg of gemcitabine was adsorbed onto the 50 mg of activated carbon.
DRUG DISTRIBUTION IN RATS
The gemcitabine concentration in the popliteal lymph nodes from five rats in each Table 1 . The mean gemcitabine concentration in the GEM-AC group was significantly higher than that in the GEM-Sol group at 0.5, 1, 2, 4 and 7 h after administration (P < 0.01, P < 0.01, P < 0.01, P < 0.01, P < 0.05, respectively). The mean concentration of gemcitabine in the GEM-AC group was approximately 10-times higher than that in the GEM-Sol group at F Guo, X Mao, J Wang et al. Concentration and distribution of carbon-adsorbed gemcitabine 0.5, 1, 2 and 4 h after administration. In the lumbar lymph nodes, the gemcitabine concentration in the GEM-AC group was also significantly higher than that in the GEM-Sol group at 0.5, 1 and 2 h after drug administration (P < 0.01 for each comparison; Table 2 ). The gemcitabine concentration at the injection site in the GEM-Sol group decreased rapidly over time (Table 3 ) and, in the GEM-AC group, the concentration was significantly higher than that in the GEM-Sol group at 1 (P < 0.05) and 
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2 h (P < 0.01) after drug administration (Table 3 ). There were no significant differences in plasma gemcitabine concentrations between the two groups at any of the five time-points after drug administration (Table 4 ).
DRUG DISTRIBUTION IN PATIENTS
Eight patients with pancreatic cancer participated in the study; each treatment group (GEM-AC and GEM-Sol) included four patients. The mean ± SD operation time was 2.5 ± 0.42 h and the mean ± SD time from injection to taking the blood and tumour samples was 2.0 ± 0.5 h. A total of 61 lymph nodes were resected during surgery in the two groups, including 40 number 10 (hilus of the spleen) lymph nodes and 21 number 11 (trunk of the splenic artery) lymph nodes. Of the 40 number 10 lymph nodes, 32 were from the GEM-AC group and metastases were found in one lymph node. There were no metastases found in the eight number 10 lymph nodes from the GEM-Sol group. Of the 21 number 11 lymph nodes, 14 were from the GEM-AC group and histopathological metastases were noted in one lymph node from the same patient as mentioned above. The seven number 11 lymph nodes from the GEM-Sol group had no metastases. The gemcitabine concentrations in plasma, tumour samples, number 10 and number 11 lymph nodes are shown in Tables 5 and 6 . Plasma gemcitabine concentrations were very low in both groups and there was no significant difference between the two groups. In tumour samples and in number 10 and 11 lymph nodes, the mean gemcitabine concentrations in the GEM-AC group were approximately 7 -10-times higher than those in the GEM-Sol group (P < 0.05, P < 0.01, P < 0.01, respectively). The gemcitabine concentrations in the two metastatic lymph nodes were 106.28 µg/g (number 10 lymph node) and 119.8 µg/g (number 11 lymph node), which were higher than the mean concentrations in these lymph nodes in the GEM-Sol group (P < 0.01, P < 0.01, respectively).
Discussion
Nanoactivated carbon particles are absorbed F Guo, X Mao, J Wang et al.
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through lymphatic capillaries and retained in the regional lymph nodes for a long period of time. 24 Lymph nodes treated in this manner turn black and are, therefore, easy to identify during radical lymph node dissection. 11, 25 Activated carbon particles can adsorb large amounts of anticancer drugs and then slowly release the drug molecules, owing to the numerous micropores that constitute their structure. 3 -5 A new dosage formulation consisting of gemcitabine adsorbed onto activated carbon particles (GEM-AC) was developed for use in the present study, and comprised 50 mg/ml of activated carbon, 30 mg/ml of polyvinylpyrrolidone K-30 and 20 mg/ml of gemcitabine. According to the adsorption isotherm for GEM-AC, most of the gemcitabine was bound to the 50 mg of activated carbon. The adsorption isotherm of GEM-AC also showed that there was a dynamic equilibrium between the 'free state' gemcitabine that was around the activated carbon particles and the gemcitabine that was adsorbed onto the activated carbon particles. When the concentration of gemcitabine in the free state was < 250 µg/ml, the activated carbon would release adsorbed gemcitabine to maintain the stable concentration. Since the adsorbed amount of gemcitabine was 79-times higher than that of the free state, the free state concentration could be expected to be maintained at about 250 µg/ml for a relatively long time-period.
Gemcitabine concentrations in the regional lymph nodes of rats were higher in the GEM-AC group than in the GEM-Sol group. This confirmed that the GEM-AC formulation was selectively delivered to the regional lymph nodes in rats and, once there, released greater amounts of gemcitabine slowly, to maintain the free concentration of gemcitabine at a relatively higher level for a longer time-period than the GEM-Sol formulation.
At the injection site, the mean gemcitabine concentrations in rats in the GEM-AC group were lower than those in the GEM-Sol group at 0.5 h after drug administration, then higher at 1, 2, 4 and 7 h. Additionally, there was no significant difference in the gemcitabine concentrations between the two groups at 0.5, 4 and 7 h after drug administration. The gemcitabine concentrations in the GEM-AC group decreased more slowly compared with those in the GEM-Sol group. In plasma, the mean gemcitabine concentrations in the GEM-AC group were lower than that of the GEM-Sol group at all times after drug administration, but these differences were not statistically significant.
The findings from the rat studies suggested that gemcitabine in the GEM-AC formulation was released slowly into the circulating blood through sustained release of the drug from the carbon particles. As GEM-AC slowly released gemcitabine over a long period of time, the gemcitabine concentration at the injection site remained at a higher level in the GEM-AC group for longer after drug administration than in the GEM-Sol group. In contrast, in the GEM-Sol group, the gemcitabine concentration at the injection site was at its highest level at 0.5 h after drug administration and then fell rapidly.
Similar results were found in distribution experiments undertaken in patients with pancreatic cancer. In the four patients receiving GEM-AC injections, drug concentrations in the lymph nodes and tumour samples were significantly higher than those in the four patients receiving GEM-Sol injections. Gemcitabine levels in the plasma of patients with pancreatic cancer did not differ significantly between the two formulations.
Since the anticancer effect of gemcitabine depends on both the duration of active exposure and the drug concentration, 26, 27 the present study indicated that administration of the GEM-AC formulation might enhance the anticancer effects of gemcitabine at the injection site and the regional lymph nodes. Further research, involving larger numbers of patients, is required.
